Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40K7E | ISIN: US17331Y1091 | Ticker-Symbol:
NASDAQ
14.11.24
17:07 Uhr
1,130 US-Dollar
-0,080
-6,61 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CITIUS ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CITIUS ONCOLOGY INC 5-Tage-Chart

Aktuelle News zur CITIUS ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ...73Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%...
► Artikel lesen
09.10.CTOR-Aktie erreicht 52-Wochen-Tief bei 1,02 US-Dollar3
01.10.CTOR stock touches 52-week low at $1.29 amid market challenges1
13.09.CITIUS ONCOLOGY, INC. - 8-K, Current Report1
CITIUS ONCOLOGY Aktie jetzt für 0€ handeln
05.09.CITIUS ONCOLOGY, INC. - 8-K, Current Report1
28.08.CTOR stock touches 52-week low at $1.67 amid market challenges1
16.08.Citius Oncology Inc. completes strategic acquisition2
16.08.CITIUS ONCOLOGY, INC. - 8-K, Current Report2
13.08.CTOR stock touches 52-week low at $3.20 amid market fluctuations1
13.08.NSE - CITIUS ONCOLOGY, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities1
12.08.Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.142LYMPHIR for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc. Shares of Citius Oncology, Inc....
► Artikel lesen
09.08.CITIUS ONCOLOGY, INC. - 10-Q, Quarterly Report1
09.08.TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market Update671New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) ("TenX"), a publicly traded special purpose acquisition company, was notified by...
► Artikel lesen
05.08.Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.246Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1